Table 4.

Main study characteristics of the ongoing randomised controlled trials

	EASY-AS38	EARLY TAVR39	DANAVR40	EVoLVeD41
Identifier	NCT04204915	NCT03042104	NCT03972644	NCT03094143
Estimated enrolment	2844 participants	900 participants	1700 participants	1000 participants
Estimated completion date	October 2029	March 2024	September 2029	October 2024
Intervention	AVR	TAVR	SAVR or TAVR	SAVR or TAVR (participants will be randomised based on the presence or absence of fibrosis on CMR)
Primary outcomes	Cardiovascular death and hospitalisation for heart failure	All-cause death, all stroke and unplanned cardiovascular hospitalisation	All-cause mortality	All-cause mortality or unplanned aortic stenosis-related hospitalisation
Key inclusion criteria	Asymptomatic severe AS. Age >18 years. LVEF ≥50%.	Asymptomatic severe AS. Age ≥65 years. LVEF ≥50%. STS risk score <10.	Asymptomatic severe AS. Age ≥18 and ≤85 years. LVEF ≥50%.	Asymptomatic severe AS. Age >18 years. LVEF ≥50% on CMR.

AS, aortic stenosis; AVR, aortic valve replacement; CMR, cardiac magnetic resonance; DANAVR, Danish National Randomized Study on Early Aortic Valve Replacement in Patients with Asymptomatic Severe Aortic Stenosis; EARLY-TAVR, Evaluation of TAVR Compared to Surveillance for Patients with Asymptomatic Severe Aortic Stenosis; EASY-AS, Early Valve Replacement in Severe Asymptomatic Aortic Stenosis Study; EVoLVeD, Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients with Severe AS; LVEF, left ventricular ejection fraction; SAVR, surgical aortic valve replacement; STS, Society of Thoracic Surgeons; TAVR, transcatheter aortic valve replacement.